Curie.Bio

Curie.Bio Drug Maker Jun Kuai has been instrumental in numerous drug discovery innovations throughout her dynamic career. Notably, she served as the discovery lead for Hotspot Therapeutics’ HST-1011, advancing it from bench to clinical trials in just four years. This promising therapy is now in Phase 1 clinical trials for solid tumors. She now shares this experience with founders. Read more about her dedication to getting new medicines to patients on our website. https://lnkd.in/gDciAz4X

Throughout Lixin Qiao’s career, he has continued to look for opportunities to expedite the #drugdiscovery process with cutting-edge technology. The pursuit of those opportunities has led him to Curie.Bio as a Drug Maker, where he helps founders leverage his know-how and cutting-edge tools in medicinal chemistry to create impactful small molecule drugs. Read more about Lixin’s background on our website. https://lnkd.in/eUYD57EM

To build a successful biotech company, you can’t do it alone. Curie.Bio provides you with instant access to the team and resources you need to get your drug to patients. Curie.Bio CSO Christoph Lengauer shares more about his background and Curie.Bio's unique approach to #FreeTheFounders in this recent episode of the Founders in Biotech podcast. Listen here and skip to 20:40 for the biotech-focused discussion. https://lnkd.in/eTJJYZWT

What does WIPSA stand for? “Walk-In-The-Park-Series-A” That’s the goal for every one of our seeded companies. To map out the TPPs and the seed milestones that would enable a WIPSA, Lisa Huang leverages her experience shaping the strategy of over 40 biotech companies across various stages during her career. Many of these startups have gone on to IPO, be acquired, and partner with large pharma. Lisa takes pride in integrating science, business and strategy to identify the best path to value inflection, both short and long-term. More on Lisa’s journey to Curie.Bio: https://lnkd.in/ecNZxyHc

“I am a passionate and experienced drug hunter. I take great joy and pride in overcoming numerous challenges in the lengthy drug discovery process to get molecules into the clinic.” Drug Maker Yue Pan has led hit finding and lead optimization across various small molecule modalities, target classes, and therapeutic areas during his 17 years in industry. Now, he partners with Curie.Bio founders to develop and execute an effective drug discovery strategy. More on Yue: https://lnkd.in/eqwRRkKp

Drug Maker in Residence Chris Borella has contributed to the discovery and development of 4 FDA-approved medicines and co-founded two biotech companies. Chris’s 20+ years of experience equips him to support founders with all aspects of their operations. Chris shares more on how he is able to tailor his support for each founder’s unique background and interests on our website. https://lnkd.in/eUSHKEdD

We’re thrilled to announce the addition of Pallavur Sivakumar to our CSO Partner team. PV‘s illustrious career in drug dicovery includes contributions to more than 25 clinical-stage assets, including the recently approved CAR T cell therapy, ABECMA®. PV is motivated by “good science, working with exceptional people, and the drive to convert strong biology to drugs.” He’ll get that in spades at Curie.Bio, where he’ll support founders in their journey to develop impactful new therapies for patients. He shares more on our website. https://lnkd.in/epqWiH-G

Meet Andrew Wylie, CXO in Residence and drug discovery and development expert. As a CXO in Residence at Curie.Bio, Andy operates directly within the portfolio companies to help founders advance their drug discovery programs. Read more about the pharma experiences that led Andy to Curie.Bio, including his work on FDA-approved oncology drug SCEMBLIX, here. https://lnkd.in/eQEAQBw7

What do you get when you combine a medicinal chemist obsessed with drug hunting, a LinkedIn celebrity and an Australian? You get Chris De Savi, one of Curie.Bio’s esteemed CSO Partners. Chris now shares his wealth of experience in bringing more than 10 drugs into the clinic with every Curie.Bio portfolio company that leverages a small molecule as part of their drug. More on Chris and the hard-earned expertise he brings to our portfolio companies: https://lnkd.in/egcrRT9E

Tired of commuting? Build blockbuster medicines with Curie.Bio, where you’ll get access to the world’s best people and R&D capabilities without having to leave your home office. Reach out to us: https://lnkd.in/e4NWnqwF